⌕
Akari Therapeutics · AKTX · Nasdaq
Tenet — · insufficient data
Compare
$6.71+0.90%At close
$6.71+0.06 (+0.90%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Akari Therapeutics (AKTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 12, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform

Initiated GLP toxicology studies of lead TROP2-targeted ADC AKTX-101 to enable planned Phase 1 trial in mid-2027 New preclinical findings demonstrate anti-tumor activity in urothelial cancer models resistant to currently…

● GlobeNewsWireNov 11, 2026 · 08:44 ETCOMPANY'S OWN WORDS
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

Discussion highlights Vat-Ho's oncology business development experience, his decision to join Akari and the potential of the Company's novel PH1 payload platform…

● GlobeNewsWireOct 30, 2026 · 09:05 ETCOMPANY'S OWN WORDS
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit

Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation…

● GlobeNewsWireOct 15, 2026 · 09:20 ETCOMPANY'S OWN WORDS
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027…

● GlobeNewsWireOct 13, 2026 · 09:01 ETCOMPANY'S OWN WORDS
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value…

● GlobeNewsWireOct 1, 2026 · 08:25 ETCOMPANY'S OWN WORDS
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

Patent filing covers PH1 payload's unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism…

● Defense WorldSep 28, 2026 · 09:20 ET
Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 10,763 shares, a dec…

● Defense WorldSep 9, 2026 · 04:02 ET
Akari Therapeutics (NASDAQ:AKTX) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $9.65 and traded as high as $12.04. Akari T…

● GlobeNewsWireSep 8, 2026 · 09:15 ETCOMPANY'S OWN WORDS
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September…

● GlobeNewsWireAug 27, 2026 · 09:01 ETCOMPANY'S OWN WORDS
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available  here…

No upcoming events in the feeds.

ANT17−7.4%
AAPL8+0.4%
FOX6−2.9%
META6−2.1%

Article counts from the last market-wide feed page, across every symbol we track and not just AKTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.